Cost-effectiveness analysis of COVID-19 screening strategy under China's dynamic zero-case policy

Front Public Health. 2023 May 9:11:1099116. doi: 10.3389/fpubh.2023.1099116. eCollection 2023.

Abstract

This study aims to optimize the COVID-19 screening strategies under China's dynamic zero-case policy through cost-effectiveness analysis. A total of 9 screening strategies with different screening frequencies and combinations of detection methods were designed. A stochastic agent-based model was used to simulate the progress of the COVID-19 outbreak in scenario I (close contacts were promptly quarantined) and scenario II (close contacts were not promptly quarantined). The primary outcomes included the number of infections, number of close contacts, number of deaths, the duration of the epidemic, and duration of movement restriction. Net monetary benefit (NMB) and the incremental cost-benefit ratio were used to compare the cost-effectiveness of different screening strategies. The results indicated that under China's COVID-19 dynamic zero-case policy, high-frequency screening can help contain the spread of the epidemic, reduce the size and burden of the epidemic, and is cost-effective. Mass antigen testing is not cost-effective compared with mass nucleic acid testing in the same screening frequency. It would be more cost-effective to use AT as a supplemental screening tool when NAT capacity is insufficient or when outbreaks are spreading very rapidly.

Keywords: COVID-19; China; agent-based model; cost-effectiveness; dynamic zero-case policy; screening strategy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • COVID-19* / diagnosis
  • COVID-19* / epidemiology
  • COVID-19* / prevention & control
  • China / epidemiology
  • Cost-Benefit Analysis
  • Cost-Effectiveness Analysis
  • Humans
  • Policy

Grants and funding

This work was supported by Ministry of Education Humanities and Social Sciences Research Planning Fund Project in 2022 (22YJAZH147), Innovation Team Project for General Universities in Guangdong Province (2022WCXTD011), and Guangdong Pharmaceutical University 2022 Higher Education Research Project (GYGJ202204).